Zygogianni Anna, Gennatas Konstantinos, Kouvaris John, Kantzou Ioanna, Antypas Christos, Tolia Maria, Kouloulias Vassilios
1st Department of Radiology, Kapodistrian University of Athens, Medical School, Aretaieion Hospital, Greece.
Medical Oncology, Kapodistrian University of Athens, Medical School, Greece.
World J Oncol. 2011 Jun;2(3):143-146. doi: 10.4021/wjon314w. Epub 2011 Jun 8.
Taxanes, both paclitaxel and doxetaxel are the medication of the future in the management of solid tumors. In high risk breast cancer patients, the combination of concurrent paclitaxel and docetaxel chemotherapy with adjuvant radiotherapy is an attractive option to sequential treatment, with potential for enforcing both local and systemic control. This case report examines the tolerance of such treatment. A 54-year-old Greek woman without a relevant medical history, presented with clinical diagnosed breast cancer staged T4NxM0. Neo-adjuvant chemotherapy was initially administered, and paclitaxel was administered concurrently with radiotherapy in order to achieve local control. During the third cycle of paclitaxel the patient developed grade III dermatitis. The tumor showed a reduction in size by 70%, however, chronic cutaneous and subcutaneous changes have not been accessed. In conclusion, adjuvant breast cancer therapy with concurrent standard dose radiotherapy and paclitaxel (175 mg/m) every three weeks, should be approached cautiously owing to paclitaxel induced dermatitis.
紫杉烷类药物，包括紫杉醇和多西他赛，是未来实体瘤治疗的药物。在高危乳腺癌患者中，同步进行紫杉醇和多西他赛化疗并联合辅助放疗，相较于序贯治疗是一个有吸引力的选择，具有加强局部和全身控制的潜力。本病例报告探讨了这种治疗的耐受性。一名54岁无相关病史的希腊女性，临床诊断为T4NxM0期乳腺癌。最初给予新辅助化疗，为实现局部控制，紫杉醇与放疗同步进行。在紫杉醇治疗的第三个周期，患者出现了III级皮炎。肿瘤大小缩小了70%，然而，慢性皮肤和皮下变化尚未评估。总之，由于紫杉醇引起的皮炎，每三周同步进行标准剂量放疗和紫杉醇（175mg/m²）的辅助乳腺癌治疗应谨慎进行。
